Oncovin Interactions
There are 491 drugs known to interact with Oncovin (vincristine), along with 8 disease interactions. Of the total drug interactions, 79 are major, 385 are moderate, and 27 are minor.
- View all 491 medications that may interact with Oncovin
- View Oncovin disease interactions (8)
Most frequently checked interactions
View interaction reports for Oncovin (vincristine) and the medicines listed below.
- Adriamycin (doxorubicin)
- Adriamycin (doxorubicin)
- Adriamycin RDF (doxorubicin)
- Adriamycin RDF (doxorubicin)
- Afinitor Disperz (everolimus)
- Afinitor Disperz (everolimus)
- bleomycin
- bleomycin
- cyclophosphamide
- cyclophosphamide
- Cytoxan (cyclophosphamide)
- Cytoxan (cyclophosphamide)
- Diacomit (stiripentol)
- Diacomit (stiripentol)
- doxorubicin
- doxorubicin
- Etopophos (etoposide)
- Etopophos (etoposide)
- Kalydeco (ivacaftor)
- Kalydeco (ivacaftor)
- Matulane (procarbazine)
- Matulane (procarbazine)
- Meticorten (prednisone)
- Meticorten (prednisone)
- Mustargen (mechlorethamine)
- Mustargen (mechlorethamine)
- Neulasta (pegfilgrastim)
- Neulasta (pegfilgrastim)
- prednisone
- prednisone
Oncovin disease interactions
There are 8 disease interactions with Oncovin (vincristine) which include:
- pulmonary dysfunction
- neurologic dysfunction
- constipation
- hepatic dysfunction
- infections
- myelosuppression
- renal impairment
- SIADH
Report options
QR code containing a link to this page
More about Oncovin (vincristine)
- Oncovin consumer information
- Check interactions
- Compare alternatives
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: mitotic inhibitors
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.